It has been widely acknowledged that capacity constraints resulting from the global shortage of manufacturing facilities for biotech products has the potential to negatively impact the course of new products into clinical development. Therefore, the ability of a Company to manufacture its own products through the crucial early stages of preclinical and clinical development has become a key asset and critical differentiating feature in the biotech industry. Viventia Biotech has built an enviable biotech manufacturing infrastructure at its Winnipeg facility, capable of meeting the Company's drug product needs from preclinical development through to the completion of advanced clinical trials. As a result, the Company is strategically poised to control the output of its proprietary technology platforms, unhindered by production capacity constraints.

Viventia has considerable expertise in the manufacturing of clinical grade monoclonal antibodies and other biotech products according to current Good Manufacturing Practices (cGMP). In order to complement the output of Viventia’s Armed Antibodies™ platform, the Company has focused its expertise and strengthened its infrastructure for the manufacturing of monoclonal antibody fragments in bacteria.